CDC recommends RSV vaccine for older adults who would benefit
As proposed by its Advisory Committee on Immunization Practices, the Centers for Disease Control and Prevention today recommended a single dose of the GSK or Pfizer Respiratory Syncytial Virus vaccine for people aged 60 and older who decide with their health care provider that the vaccine would benefit them. The Food and Drug Administration last month approved the vaccines for use in individuals 60 and older. The first U.S.-licensed vaccines to protect against RSV, they are expected to be available this fall.
Related News Articles
Chairperson's File
A strong and healthy workforce is the backbone of American health care.
We know that an aging workforce, combined with a surge in retirements and the stress…
Chairperson's File
This week, as many of us gather with family and friends to celebrate Thanksgiving, let’s give thanks for the incredible dedication, compassion and expertise of…
Perspective
In Colorado, determined pediatric cardiologists worked around-the-clock to save the life of a baby girl born with a potentially fatal heart valve deformity,…
Headline
The departments of Health and Human Services, Labor, and the Treasury today released a request for information on the potential benefits and costs of…
Blog
Every day, America’s health care workers offer care and comfort to millions of patients and loved ones. They draw not only on their expertise, but also on…
Headline
The Department of Health and Human Services yesterday released a report on evidence-based strategies to increase physical activity among older adults in…